Inosine glicyl-cysteinyl-glutamate disodium (Molixan) injections 30 mg/ml 2 ml – [5 ampoules]

Description

Molixan Pharmacodynamics
Molixan® is an organic salt including inosine (purine component) and glycyl-cysteinyl-glutamate (peptide component) in a 1:1 ratio. Molixan® regulates thiol-disulfide metabolism of hepatocytes, induces expression of enzymes of the first and second phases of xenobiotic detoxification, inhibits DNA and RNA replication of viruses causing hepatitis B and C, stimulates production of interferons and liver macrophages, interleukin-2 by T-lymphocytes. Cytoprotective and immunomodulatory activities of Molixan® result in inhibition of cytolysis of hepatocytes, resolution of inflammatory process in toxic and viral lesions of liver cells. Peptide and purine components of Molixan® mediate metabolism, proliferation, differentiation and apoptosis of liver cells, contributing to restoration of normal hepatic tissue structure. The drug has immunomodulatory, antiviral, hepatoprotective cardioprotective and neuroprotective effects.
During clinical application – treatment of acute alcohol intoxication (alcoholic coma) against standard detoxification therapy Molixan® decreases time of patients’ recovery from coma, normalizes bioelectric activity of brain and cardiac conduction system, promotes normalization of blood gas composition and acid-base balance, lactate level, potassium content, transaminase activity, alkaline
phosphatase, gamma-glutamyltranspeptidase, bilirubin level and its fractions, stops the development of changes characteristic of withdrawal syndrome, eliminates anxiety, vascular disorders.
During acute and chronic ethanol intoxication in experimental animals, hepatoprotective effect of Molixan® preparation was shown in reduction of total bilirubin concentration and decrease of blood transaminases activity (ALT/AST). According to preclinical studies, intravenous administration of the drug at a dose of 30 mg/kg increased resistance of rat myocardium to myocardial ischemia-reperfusion injury by reducing the size of the necrosis zone, and had a mild hypotensive effect. In experimental animals injected into alcohol withdrawal, the drug contributed to a decrease in the level of neuroglial cell damage markers: neuronspecific enolase and protein S-100B, and a more rapid normalization of neurological symptomatology.

Indications
– Severe acute alcohol intoxication (as part of complex therapy);
– Acute and chronic viral hepatitis B, C;

Contraindications
– Pregnancy and breast-feeding;
– In children due to lack of experience in medical use;
– Individual intolerance to the drug components.
Administration during pregnancy and lactation
SCAN® is contraindicated for the use of the drug during pregnancy and breast-feeding because of lack of clinical data concerning safety in these groups of patients.

Dosage and administration regimen

• Intravenously and intramuscularly.
• For intravenous injection 0.9% sodium chloride solution or 5% dextrose solution is used as a solvent.
• Recommended treatment regimens:
  In treatment of acute alcohol intoxication – alcoholic coma, against the background of standard detoxification therapy: the drug Molixan® in a dose of 3.0 mg/kg is administered once intravenously (by trickle) with 0.9% sodium chloride solution or with 5% dextrose solution in a 1:1 ratio by volume.
• In acute viral hepatitis B the drug Molixan® is administered intravenously or intramuscularly once 10 mg/day every other day during the whole course of symptomatic and detoxification therapy.
• In severe forms of acute viral hepatitis B the preparation Molixan® is administered intravenously or intramuscularly 20 mg/day once daily during the course of symptomatic and detoxification therapy.
• In complex antiviral therapy of chronic viral hepatitis B the preparation Molixan® is administered intravenously or intramuscularly 30 mg/d three times a week, every other day during the whole course of specific antiviral therapy.
• In monotherapy of chronic viral hepatitis B that is resistant to means of specific antiviral therapy or in case of impossibility of its carrying out due to medical indications: Molixan® is administered intravenously or intramuscularly once 30 mg/day three times a week, every other day, the course of treatment is 24 weeks.
• In complex antiviral therapy of chronic viral hepatitis C: Molixan® is administered intravenously or intramuscularly 60 mg/d three times a week, every other day during the whole course of specific antiviral therapy.
• In monotherapy of chronic viral hepatitis C that is resistant to specific antiviral therapy or in case of impossibility to perform it by medical indications: Molixan® is administered intravenously or intramuscularly once daily 60 mg/day, three times a week, every other day, the course of treatment is 24 weeks.